Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.